TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.
about
Probiotics for patients with hepatic encephalopathyFER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-kappaBToll-Like Receptors in the Pathogenesis of Autoimmune DiseasesAccelerated atherosclerosis in patients with SLE--mechanisms and managementMaking sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromesToll-Like Receptors and Viruses: Induction of Innate Antiviral Immune ResponsesEmerging therapies for systemic lupus erythematosus--focus on targeting interferon-alphaMechanisms of tissue injury in lupus nephritisBANK1 controls CpG-induced IL-6 secretion via a p38 and MNK1/2/eIF4E translation initiation pathwayEffect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma.The therapeutic potential of Toll-like receptor 7 stimulation in asthma.Down-regulated NOD2 by immunosuppressants in peripheral blood cells in patients with SLE reduces the muramyl dipeptide-induced IL-10 production.Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjogren's syndrome.Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine: implications for the design and discovery of novel antiviral drugsQuinacrine impairs enterovirus 71 RNA replication by preventing binding of polypyrimidine-tract binding protein with internal ribosome entry sites.Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malariaDendritic cell control of tolerogenic responses.The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.TLR9 and the NLRP3 inflammasome link acinar cell death with inflammation in acute pancreatitis.CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanismActivation of TLR2 and TLR6 by Dengue NS1 Protein and Its Implications in the Immunopathogenesis of Dengue Virus Infection.Antagonist-mediated down-regulation of Toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus.Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.Toll-like receptors: another player in the pathogenesis of the anti-phospholipid syndrome.Effect of glucocorticoid on cytokines TLR9 and TLR7 in peripheral blood for patients with uveitis.MicroRNA-181b negatively regulates the proliferation of human epidermal keratinocytes in psoriasis through targeting TLR4.Type I interferons: crucial participants in disease amplification in autoimmunity.Mouse models of systemic lupus erythematosus reveal a complex pathogenesis.Developments in virus-like particle-based vaccines for infectious diseases and cancer.Small molecule anti-malarial patents: a review (January 2010-June 2011).Emerging immunosuppressive drugs in myelodysplastic syndromes.Developments in virus-like particle-based vaccines for HIV.VLPs and particle strategies for cancer vaccines.Dendritic cells, T-cells and epithelial cells: a crucial interplay in immunopathology of primary Sjögren's syndrome.Pathogenesis and treatment of atherosclerosis in lupus.Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.Nucleic acid-sensing TLRs and autoimmunity: novel insights from structural and cell biology.The Link Between Inflammatory Disorders and Coronary Heart Disease: a Look at Recent Studies and Novel Drugs in Development.A Quinacrine Analogue Selective Against Gastric Cancer Cells: Insight from Biochemical and Biophysical Studies.
P2860
Q24235259-C3325E3E-2E09-4AAE-A874-326C6E202248Q24300387-224BE994-67AB-4D09-8AB0-BDDFC2D1B91CQ26770257-ABC6073F-8A30-4B57-9190-FE5042A702CEQ26820245-C6EE98F7-35A2-4B1A-B760-F72A57C27A4EQ27011625-380FA3B4-A939-44FA-A505-35A7C3519BC9Q27487393-298E7D34-17B2-4B69-8EF2-288D35F6FE6EQ28265144-045FB2E2-2993-45B5-A7D7-BE665C618424Q28383739-C6009839-8320-447E-8E4E-C4DE5894EDCCQ28512739-95B1B68F-5B0D-4428-B940-7E9BEB747605Q31170767-A8E67A72-4064-4910-B892-A62EF860EE65Q33725167-54E36DAB-BD7B-4041-B2D9-E3EFE3E25AC3Q34008997-919EE345-1047-433B-B331-7571560CB387Q34103317-90D1CE83-95FB-4800-8F84-02D9C27DEC0BQ34120213-84E58FAA-7441-4BD0-A8C9-B17A5AC93AD7Q34542235-737A2363-18E9-4478-9432-524F02D34FCCQ34621573-1C5E066A-E9F1-4CB5-8EEE-B6054746D641Q34982085-91B9EDD8-F5E8-46CD-9227-8D14F9B5EE46Q35018021-344F3276-B068-40FE-BB7E-CC4755CEE978Q35055978-361D2B10-DEE6-4EFF-A747-1C7158316A04Q35085962-CBF78ABD-1A38-41DC-B019-5D782DF3198AQ35204579-2E3CED5B-6C82-4C1A-A86E-5152E32580AFQ35727211-CEBE8106-5844-4339-9B61-CA694909776EQ36245824-6CB5B795-99E1-4A63-AFAC-FC2DFE9375C4Q37033345-72820C6D-4943-437A-A47C-11C697CDA7B7Q37283036-BD31DEEC-D114-4C6C-8DCD-1A8C42741ED4Q37581601-515776E8-1D11-4176-834F-BFD8014F9732Q37604349-77C6F43D-DD04-40D4-9CE0-0E075968FA4EQ37666513-E57AB3C3-ED9F-4F2C-AE17-D497699ADA4BQ37744348-646280C6-C20A-417E-A4D4-83A0220E4B1DQ37951525-498E441D-0556-4C93-A846-AE9802378075Q38018392-9C63A07C-338F-49A2-A69B-80E08ED93469Q38060835-EEE8EA4F-3AA4-4763-B28E-41B43BF2A561Q38081965-DDCE3F46-E724-4EF2-BB2D-6F8BFB834E24Q38152475-7C03865A-5E37-43C5-88B7-478719438D82Q38180723-3F3C559E-6625-4A04-A178-78972916C9D2Q38230699-507D09F6-FA35-45F6-BD09-973F20F92DA9Q38561490-7BA5F505-EFB6-44DC-8433-F9C3D226E1FBQ38673412-F91FB377-77CF-4F67-9D88-DCB554FFB904Q38688816-AC6A884A-B312-4694-B21E-36FD012A7623Q38730329-01383FA0-3D11-4AE7-94AB-1F759A80BBAD
P2860
TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.
@en
TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.
@nl
type
label
TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.
@en
TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.
@nl
prefLabel
TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.
@en
TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.
@nl
P2093
P1476
TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.
@en
P2093
Jennifer Venable
Navin L Rao
Siquan Sun
P304
P356
10.2174/187152807783334300
P577
2007-12-01T00:00:00Z